EVIDENCE SPOTLIGHT: Vibroacoustic Therapy and Fibromyalgia Symptoms
STUDY OVERVIEW
Fibromyalgia is a chronic condition associated with widespread pain, fatigue, disrupted sleep, reduced physical function, mood changes, and difficulty completing everyday activities.
This clinical pilot study examined whether low-frequency sound stimulation—also described by the authors as vibroacoustic therapy—could support women living with fibromyalgia. Nineteen participants received ten sessions of 40 Hz stimulation over five weeks.
Following treatment, the researchers observed improvements across multiple areas, including the overall impact of fibromyalgia, sleep, pain-related disability, physical mobility, muscle tension, and participants’ ability to sit and stand without pain. Because the study did not include a control group, the results should be viewed as promising preliminary evidence rather than proof of effectiveness.
STUDY DETAILS
Study Type: Open-label pilot clinical study with a repeated-measures design
Participants: 19 women diagnosed with fibromyalgia
Median Age: 51 years
Median Duration of Fibromyalgia: 5.76 years
Treatment Frequency: Two sessions per week
Session Length: 23 minutes
Number of Sessions: 10
Treatment Duration: Five weeks
Frequency Used: 40 Hz
Equipment: SL5 lounge manufactured by Nexneuro
Participant Position: Reclined in a supine position
Comparison Group: None
Primary Focus: Fibromyalgia symptoms, sleep, pain-related disability, and physical function
WHAT THEY DID
Participants received two 23-minute low-frequency sound stimulation sessions per week for five weeks. The 40 Hz stimulation was delivered through transducers built into a therapeutic lounge.
Participants reclined on the lounge and were instructed simply to relax. They experienced a mild vibration throughout the body and heard a low-level hum. The same power setting was used for every participant, although the researchers did not measure or report the exact decibel level.
Blood pressure and pulse were documented before and after each session.
Before treatment, participants completed a physical examination and several standardized questionnaires. Their pain, mood, insomnia, daily activities, medication use, ability to sit and stand without pain, cervical range of motion, and muscle tone were also assessed.
The full assessment was repeated immediately after the tenth treatment. Two weeks later, participants were asked when pain or sleep problems had returned, and the Pain Disability Index was administered again.
OUTCOMES MEASURED
The researchers measured:
The overall impact of fibromyalgia using the Fibromyalgia Impact Questionnaire
Sleep problems using the Jenkins Sleep Scale
Pain-related disability using the Pain Disability Index
Self-reported changes in pain, mood, insomnia, and activities of daily living
Medication use
Time participants could sit without pain
Time participants could stand without pain
Cervical range of motion
Cervical muscle tone
Missed workdays
Participants’ overall impression of change
The recurrence of pain or sleep disturbance after treatment ended
The standardized questionnaires and physical assessments were completed before treatment and immediately after the tenth session. A limited follow-up assessment was conducted two weeks later.
MAJOR FINDINGS
Overall fibromyalgia impact improved
Median Fibromyalgia Impact Questionnaire scores decreased from 88.8 before treatment to 16.8 after treatment, representing an 81% reduction in fibromyalgia-related impact. This change was statistically significant at p < 0.0001.
Sleep problems decreased
Median Jenkins Sleep Scale scores decreased from 20 to 2, representing a 90% improvement in reported sleep problems.
This change was statistically significant at p < 0.0001.
Pain-related disability decreased
Pain Disability Index scores improved by approximately 49% following treatment.
This change was also statistically significant at p < 0.0001.
Pain and fatigue ratings improved
On individual Fibromyalgia Impact Questionnaire items:
Median pain scores decreased from 9 to 2
Median tiredness scores decreased from 10 to 2
Both changes were statistically significant at p < 0.0001.
Physical function improved
Participants were able to sit and stand without pain for significantly longer periods after treatment.
Median cervical range of motion increased from 25% to 75%, while median cervical muscle tone changed from hypertonic to normal.
The range-of-motion change was statistically significant at p = 0.001, and the muscle-tone change was statistically significant at p = 0.0002.
ADDITIONAL REPORTED BENEFITS
The researchers also reported:
Median missed workdays decreased from four days per week to one day per week
73.68% of participants reported reducing their pain medication dosage
26.32% of participants reported discontinuing pain medication
Median self-reported improvements in pain and daily activities exceeded 70%
Median improvements in mood and insomnia exceeded 65%
Nearly 90% of participants described their condition as “much better” or “very much better”
No participants reported that their condition had worsened
The medication findings were based on participant self-report. The study does not explain whether medication changes were supervised by the participants’ prescribing clinicians.
The researchers reported no adverse effects. Participants also reported no discomfort or annoyance from the mild vibration or low-level sound used during treatment.
How long did the improvements last?
The two-week follow-up showed that pain or sleep symptoms returned for most participants.
Three participants reported no recurrence of symptoms during the 14-day follow-up period. Among those whose symptoms returned:
Pain returned after an average of approximately eight days
Sleep disturbance returned after an average of approximately 10 days
These findings suggest that continued or maintenance sessions may need to be studied, but the researchers did not test a long-term maintenance protocol.
CLINICAL IMPLICATIONS
This study suggests that 40 Hz low-frequency sound stimulation may offer complementary support for several concerns commonly associated with fibromyalgia, including widespread pain, disrupted sleep, fatigue, muscle tension, limited mobility, and difficulty completing daily activities.
The improvements extended beyond symptom ratings. Participants also demonstrated changes in physical measures such as cervical range of motion, muscle tone, and the length of time they could sit or stand without pain.
The recurrence of symptoms after treatment ended is also clinically important. It suggests that the intervention’s effects may be temporary for some people and that future research should evaluate treatment frequency, maintenance schedules, and longer-term outcomes.
Several limitations substantially affect how the results should be interpreted:
The study included only 19 participants.
All participants were women.
There was no placebo or comparison group.
Participants and researchers knew that active treatment was being delivered.
Some outcomes relied on subjective self-report.
The study did not include a separate baseline-control period or repeated pretreatment measurements.
The treatment’s sound intensity was not measured.
Follow-up was limited to two weeks.
Medication reductions were self-reported.
The study could not determine whether improvements resulted from 40 Hz stimulation, relaxation, expectations, attention from clinicians, or a combination of factors.
The intervention should therefore be understood as an investigational, complementary approach—not a replacement for medical care, medication management, physical activity, sleep support, or other established elements of fibromyalgia treatment.
RELEVANCE TO SICKLE CELL SUPPORT
This study did not involve people with sickle cell disease. It was selected because several concerns examined in the fibromyalgia population—chronic pain, fatigue, sleep disruption, reduced mobility, muscle tension, pain-related disability, and difficulty with daily activities—may also affect people living with sickle cell disease.
The study’s findings are relevant to broader supportive-care goals because participants reported improvements in pain impact, sleep, fatigue, physical function, and daily activity after receiving low-frequency sound stimulation.
However, fibromyalgia and sickle cell disease have different underlying causes and pain mechanisms. These findings do not establish that vibroacoustic therapy treats sickle cell disease, prevents pain crises, or reduces vaso-occlusive pain.
Instead, the study offers preliminary evidence supporting further investigation of VAT for comfort, rest, chronic symptom management, physical function, and quality-of-life support in populations experiencing persistent pain. Research conducted specifically with people living with sickle cell disease is still needed.
WHY IT MATTERS
Fibromyalgia affects more than pain alone. It can disrupt sleep, reduce energy, restrict movement, interfere with work, and make ordinary daily activities difficult.
This study is notable because the researchers examined multiple dimensions of the condition rather than relying on one pain rating. Improvements were reported in fibromyalgia impact, sleep, pain-related disability, fatigue, medication use, missed work, sitting and standing tolerance, range of motion, and muscle tone.
The return of symptoms after treatment ended provides an equally important finding. It indicates that symptom improvement may require continued treatment and highlights the need for research into maintenance dosing and long-term effects.
Although the results were substantial, the study’s small size and uncontrolled design mean that they cannot establish cause and effect. The findings support additional controlled trials rather than definitive clinical claims about 40 Hz stimulation or VAT for fibromyalgia.
PUBLICATION & RESEARCH ACCESS
Study: The Effect of Low-Frequency Sound Stimulation on Patients with Fibromyalgia: A Clinical Study
Authors: Lili Naghdi, Heidi Ahonen, Pasqualino Macario, and Lee Bartel
Journal: Pain Research and Management
Year: 2015
Volume and Issue: Volume 20, Issue 1
Pages: e21–e27
Study Classification: Open-label pilot clinical study with a repeated-measures design
DOI: 10.1155/2015/375174
PubMed ID: 25545161
PubMed Central ID: PMC4325896
Research Access: The full study is available through PubMed Central.